Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Pharma Industry News Nutshell Therapeutics secures FDA IND clearance for NTS071, targeting p53 Y220C mutation in cancer treatment Find out how Nutshell Therapeutics’ NTS071 is redefining precision oncology by targeting the p53 Y220C mutation with a novel allosteric small molecule. byPallavi MadhirajuMay 4, 2025